Correction: Network pharmacology, bioinformatics and in vitro/in vivo validation elucidate the anti-lung cancer activities and potential targets of Rhoifolin.

There was a mistake in Figures 2, 3, 6 as published. In Figures 2F,G, 3D, 6A,D, the compound name “Rhoifolin” was incorrectly spelled as “Phoifolin” in the bar graph for cell lines H358 and H1299. In Figure 2B, the legend label for the “48 h” time point was incorrectly written as “48 4”. In Figure 3D, the asterisks indicating statistical significance on the bar graph were omitted. The corrected Figures 2, 3, 6 appear below.
The original article has been updated.